Rhenman & Partners Asset Management AB Decreases Position in Vertex Pharmaceuticals Incorporated (VRTX)

Share on StockTwits

Rhenman & Partners Asset Management AB lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 132,425 shares of the pharmaceutical company’s stock after selling 10,040 shares during the period. Vertex Pharmaceuticals makes up approximately 2.5% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 8th largest holding. Rhenman & Partners Asset Management AB’s holdings in Vertex Pharmaceuticals were worth $21,944,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. increased its position in Vertex Pharmaceuticals by 21.1% during the 2nd quarter. Advisors Asset Management Inc. now owns 15,434 shares of the pharmaceutical company’s stock worth $2,623,000 after purchasing an additional 2,694 shares in the last quarter. Schroder Investment Management Group increased its position in Vertex Pharmaceuticals by 7.3% during the 2nd quarter. Schroder Investment Management Group now owns 27,309 shares of the pharmaceutical company’s stock worth $4,031,000 after purchasing an additional 1,849 shares in the last quarter. Atria Investments LLC increased its position in Vertex Pharmaceuticals by 55.4% during the 3rd quarter. Atria Investments LLC now owns 6,082 shares of the pharmaceutical company’s stock worth $1,172,000 after purchasing an additional 2,168 shares in the last quarter. Bank of Montreal Can increased its position in Vertex Pharmaceuticals by 23.4% during the 3rd quarter. Bank of Montreal Can now owns 309,881 shares of the pharmaceutical company’s stock worth $59,726,000 after purchasing an additional 58,738 shares in the last quarter. Finally, Sheets Smith Wealth Management acquired a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $613,000. Institutional investors own 95.40% of the company’s stock.

VRTX opened at $181.34 on Monday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $144.07 and a fifty-two week high of $195.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 2.98. The company has a market cap of $46.34 billion, a price-to-earnings ratio of 64.08, a price-to-earnings-growth ratio of 2.16 and a beta of 1.65.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Tuesday, February 5th. The pharmaceutical company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.24. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The firm had revenue of $870.11 million for the quarter, compared to analyst estimates of $818.29 million. During the same period in the previous year, the firm posted $0.61 EPS. The company’s revenue for the quarter was up 33.5% compared to the same quarter last year. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.22 EPS for the current fiscal year.

In other news, SVP Paul M. Silva sold 809 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $186.52, for a total value of $150,894.68. Following the sale, the senior vice president now directly owns 16,896 shares of the company’s stock, valued at approximately $3,151,441.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Paul M. Silva sold 1,289 shares of the company’s stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $193.00, for a total transaction of $248,777.00. Following the completion of the sale, the senior vice president now directly owns 13,938 shares in the company, valued at $2,690,034. The disclosure for this sale can be found here. Insiders have sold a total of 57,217 shares of company stock worth $10,645,753 over the last three months. Insiders own 0.75% of the company’s stock.

A number of equities analysts recently issued reports on VRTX shares. Zacks Investment Research reiterated a “buy” rating and set a $191.00 price objective on shares of Vertex Pharmaceuticals in a research report on Saturday, November 17th. BidaskClub upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $217.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 27th. Oppenheimer set a $200.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 27th. Finally, HC Wainwright upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $220.00 price objective for the company in a research report on Friday, October 26th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus price target of $203.76.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Zolmax and is the sole property of of Zolmax. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://zolmax.com/investing/rhenman-partners-asset-management-ab-decreases-position-in-vertex-pharmaceuticals-incorporated-vrtx/2891845.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Article: No Load Funds

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Virtusa Co.  Insider Raj Rajgopal Sells 9,490 Shares
Virtusa Co. Insider Raj Rajgopal Sells 9,490 Shares
Genomic Health, Inc.  CFO G Bradley Cole Sells 15,000 Shares
Genomic Health, Inc. CFO G Bradley Cole Sells 15,000 Shares
Stellar Market Cap Reaches $1.47 Billion
Stellar Market Cap Reaches $1.47 Billion
Wynn Resorts  Shares Gap Down to $127.55
Wynn Resorts Shares Gap Down to $127.55
Investors Buy iShares Edge MSCI Min Vol USA ETF  on Weakness
Investors Buy iShares Edge MSCI Min Vol USA ETF on Weakness
Bitcoin Cash Market Cap Hits $2.16 Billion
Bitcoin Cash Market Cap Hits $2.16 Billion


Leave a Reply

 
© 2006-2019 Zolmax.